Literature DB >> 6344776

Structural variants of human growth hormone: biochemical, genetic, and clinical aspects.

R K Chawla, J S Parks, D Rudman.   

Abstract

Human growth hormone (hGH) is a mixture of peptides in which the major physiologic component is a single chain polypeptide of 191 residues with a molecular weight of 22,000 ("22K" form). The minor components differ from the 22K form in terms of mass (e.g. the 20K form, a single-chain peptide synthesized by deletion of residues 32-46 of the 22K isomer, and the 45K variant formed by aggregation of the 22K molecule), or of charge (e.g. the more acidic two-chain forms alpha 2 and alpha 3 which are generated by proteolytic deletion of residues 135-140 and 135-146 from the 22K variant). The minor components also differ from the 22K molecule in (a) their metabolic effects; (b) their capacity to bind to antiserum raised against the 22K form in a radioimmunoassay (RIA); and (c) their ability to bind to membrane receptors for the 22K hGH in a radioreceptor assay (RRA). Two genes, N and V, involved in the biosynthesis of hGH, are located on human chromosome 17. Heritable alterations of the N gene may cause deficiency of immunoreactive hGH and growth failure. A pathologic variant of hGH has also been identified which is indistinguishable from the 22K form on RIA, but which has low reactivity on hGH-RRA and low somatomedogenic activity. Several mechanisms to account for this bioinactive variant are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344776     DOI: 10.1146/annurev.me.34.020183.002511

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  12 in total

1.  A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor.

Authors:  S H Bass; M G Mulkerrin; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

2.  Immunohistochemical colocalization of growth hormone (GH) and alpha subunit in human GH secreting pituitary adenomas.

Authors:  R Y Osamura; K Watanabe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 3.  Comparison of the intermediate complexes of human growth hormone bound to the human growth hormone and prolactin receptors.

Authors:  A A Kossiakoff; W Somers; M Ultsch; K Andow; Y A Muller; A M De Vos
Journal:  Protein Sci       Date:  1994-10       Impact factor: 6.725

4.  Changes in endochondral bone elongation rates during pregnancy and lactation in rats.

Authors:  E H Redd; S C Miller; W S Jee
Journal:  Calcif Tissue Int       Date:  1984-12       Impact factor: 4.333

5.  Rational design of receptor-specific variants of human growth hormone.

Authors:  B C Cunningham; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

6.  Evidence from the use of monoclonal antibody probes for structural heterogeneity of the growth hormone receptor.

Authors:  R Barnard; P G Bundesen; D B Rylatt; M J Waters
Journal:  Biochem J       Date:  1985-10-15       Impact factor: 3.857

7.  Stimulation of 2-deoxyglucose uptake in rat adipocytes by a human growth hormone fragment (hGH 4-15).

Authors:  F M Ng; J A Harcourt
Journal:  Diabetologia       Date:  1986-12       Impact factor: 10.122

8.  Proteolysis of human growth hormone by rat thyroid gland in vitro: application of electrospray mass spectrometry and N-terminal sequencing to elucidate a metabolic pathway.

Authors:  V J Wroblewski; R E Kaiser; G W Becker
Journal:  Pharm Res       Date:  1993-08       Impact factor: 4.200

9.  Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor.

Authors:  Y K Fu; S Arkins; G Fuh; B C Cunningham; J A Wells; S Fong; M J Cronin; R Dantzer; K W Kelley
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

10.  Identification and characterization of specific binding proteins for growth hormone in normal human sera.

Authors:  A C Herington; S Ymer; J Stevenson
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.